{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T04:21:45Z","timestamp":1795234905350,"version":"4.10.3"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009583","name":"Public Interest Incorporated Foundation Morinaga Foundation for Health and Nutrition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009583","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K08137"],"award-info":[{"award-number":["19K08137"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K07213"],"award-info":[{"award-number":["21K07213"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03036"],"award-info":[{"award-number":["22H03036"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118505","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T23:15:38Z","timestamp":1756422938000},"page":"118505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A novel method for generating chimeric antigen receptor-transduced primary human natural killer cells by the use of multiple cytokines and anti-CD2 and anti-NKp46 stimulatory antibodies"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4779-272X","authenticated-orcid":false,"given":"Nobuhiro","family":"Kubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-7968","authenticated-orcid":false,"given":"Minori","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4008-8978","authenticated-orcid":false,"given":"Chansu","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3564-1701","authenticated-orcid":false,"given":"Ryosuke","family":"Hosokai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-392X","authenticated-orcid":false,"given":"Naoki","family":"Oike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keichiro","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-680X","authenticated-orcid":false,"given":"Masaru","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-3464","authenticated-orcid":false,"given":"Chihaya","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118505_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118505_bib2","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2025.118505_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2025.118505_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.biopha.2025.118505_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118505_bib6","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2025.118505_bib7","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.biopha.2025.118505_bib8","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.biopha.2025.118505_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118505_bib10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ b cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2025.118505_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2025.118505_bib12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2014-02-556837","article-title":"Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15","volume":"124","author":"Imamura","year":"2014","journal-title":"Blood 14"},{"issue":"2","key":"10.1016\/j.biopha.2025.118505_bib13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.118505_bib14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3389\/fimmu.2020.01090","article-title":"CD2 immunobiology","volume":"11","author":"Binder","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118505_bib15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","article-title":"The natural cytotoxicity receptors in health and disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118505_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.biopha.2025.118505_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-Bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.biopha.2025.118505_bib18","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.biopha.2025.118505_bib19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.118505_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.intimp.2014.07.036","article-title":"Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded \u03b3\u03b4 t cells or \u03b1\u03b2 t cells","author":"Deng","year":"2014","journal-title":"Int Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118505_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcyt.2015.09.011","article-title":"Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies","volume":"18","author":"Masuyama","year":"2016","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.biopha.2025.118505_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1186\/s12885-019-6034-1","article-title":"Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer","volume":"19","author":"Choi","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2025.118505_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.803380","article-title":"Feeder-Cell-Free and Serum-Free expansion of natural killer cells using cloudz microspheres, G-Rex6M, and human platelet lysate","volume":"13","author":"Johnson","year":"2022","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118505_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cells13020146","article-title":"Allogeneic CAR-T therapy technologies: has the promise been met?","volume":"13","author":"Lonez","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2025.118505_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.111207","article-title":"Chimeric antigen receptor natural killer cell therapy: a systematic review of preclinical studies for hematologic and solid malignancies","volume":"86","author":"Karamivandishi","year":"2025","journal-title":"Hum. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118505_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/hgtb.2019.039","article-title":"Development of automated separation, expansion, and quality control protocols for Clinical-Scale manufacturing of primary human NK cells and alpharetroviral chimeric antigen receptor engineering","volume":"30","author":"Oberschmidt","year":"2019","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.biopha.2025.118505_bib27","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3389\/fimmu.2019.03123","article-title":"High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-Specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia","volume":"10","author":"M\u00fcller","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118505_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci. Rep."},{"issue":"24","key":"10.1016\/j.biopha.2025.118505_bib29","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2025.118505_bib30","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/cancers13040872","article-title":"RNA-Seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking","volume":"13","author":"Levy","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:52:36Z","timestamp":1772819556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225006997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"alternative-id":["S0753332225006997"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118505","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel method for generating chimeric antigen receptor-transduced primary human natural killer cells by the use of multiple cytokines and anti-CD2 and anti-NKp46 stimulatory antibodies","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118505"}}